Bifogade filer
Annexin participates in several investor and industry events
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Annexin Pharmaceuticals AB (publ) today announces that the company will participate in several leading international investor and industry events this summer. The aim is to increase awareness of the company and the drug candidate ANXV, as well as to deepen dialogues with potential partners and investors.
- BIO International Convention 2025, June 16-19, Boston, USA
One of the world's largest biotech congresses with participants from the entire pharmaceutical industry.
Read more here: BIO 2025 - Clinical Trials at the Summit (CTS) 2025, June 19-22, Las Vegas, USA
A leading forum for clinical trials in eye diseases, with a focus on innovation and collaboration. Annexin has been selected and invited to present.
Read more here: Clinical Trials at the Summit 2025 - Ophthalmology Innovation Source, OIS Retina Innovation Summit 2025, July 29, Long Beach, California, USA
An exclusive event for innovation in ophthalmology, bringing together leading players in the retina field. Annexin has been selected and invited to present.
Read more here: OIS Retina Innovation 2025 - American Society of Retina Specialists, ASRS 2025, July 30 – August 1, Long Beach, California, USA
Immediately after the above event, eye care specialists will continue to gather to spark new conversations and create opportunities for future collaboration.
Read more here: ASRS 2025 - EURETINA 2025, 4-7 September, Paris, France
Europe's largest scientific congress in retina, focusing on clinical research and new treatments. Annexin has been selected and invited to present.
Read more here: Euretina 2025
"We look forward to presenting our progress and discussing ANXV's potential with both industry peers and investors at these important meetings. It is part of our strategy to increase the international visibility of our project in retinal vein occlusion (RVO) and other eye diseases," says Anders Haegerstrand, CEO of Annexin Pharmaceuticals.
For further information, please contact:
Anders Haegerstrand, CEO
Phone: +46 70 575 50 37
E-mail: anders.haegerstrand@annexinpharma.com
Anna Frostegård, CSO/CMO
Phone: +46 70 110 42 58
E-mail: anna.frostegard@annexinpharma.com